Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4WT7Z)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA topoisomerase II beta (TOP2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[2]
XK-469	DMVYO41	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
XB-947	DM1UIOA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[5]
3'-THIO-THYMIDINE-5'-PHOSPHATE	DM5SM8X	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[7]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[8]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[6]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[9]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[6]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[10]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[1]
DNA topoisomerase II beta (TOP2B)	TT4NVEM	TOP2B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.
2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3	A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32.
4	XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173.
5	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
8	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
9	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
10	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
11	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.